PositiveID is promoting what it has to sell: mobile labs. Firefly is the technology of the future; it will bring in revenue when funded. The handheld diagnostic device is not available yet so mobile labs are still necessary. In addition there are many more uses for mobile labs. See today's PR below:
PositiveID to Present and Exhibit at the Next Generation Dx Summit August 23-26
8:30 am ET August 18, 2016 (Globe Newswire) Print
PositiveID Corporation ("PositiveID" or "Company") (OTCQB:PSID), a life sciences company focused on detection and diagnostics, announced today that it will present and exhibit as a premier sponsor at the Next Generation Dx Summit from August 23-26, 2016, at the Grand Hyatt Washington in Washington, D.C. PositiveID's President, Lyle L. Probst, will feature the Company's E-N-G Mobile Systems subsidiary, a leader in mobile laboratories, in his presentation: "Mobile Labs: Bringing Labs to the Point of Need."
PositiveID's Chief Scientist, Dr. Kimothy Smith, will be a panel speaker during the "Disruptive Innovation in Laboratory Medicine: Game-Changing Technologies and Approaches" session. The Company will also exhibit its mobile labs, molecular diagnostics and medical device businesses.
PositiveID's E-N-G Mobile Systems ("ENG") business is a leader in engineering and producing its proprietary MobiLab(TM) Systems, mobile labs for biological, chemical, radiological and nuclear testing applications. Over 400 ENG MobiLabs are in operation throughout the world. ENG was the first company to install gas chromatography in a mobile lab, and is a pioneer in developing mobile platforms that allow standard laboratory-grade instruments to be operated successfully in the field.
During the plenary session, Smith will feature PositiveID's Firefly Dx, a point-of-need ("PON"), handheld system designed to deliver molecular diagnostic results from a sample in less than 30 minutes, compared to hours or even days for a lab device, using real-time PCR (polymerase chain reaction) chemistry. Firefly's applications include PON, lab-quality, detection of pathogenic organisms; agricultural and food screening in both domestic sectors and developing countries; and detection of biological agents associated with weapons of mass destruction.
The Next Generation Dx Summit convenes more than 1,000 international diagnostic professionals for valuable networking and comprehensive programming spanning from clinical diagnostics to business strategy. Now in its eighth year, the event has grown to include novel immunotherapy biomarkers, cell-free DNA, companion diagnostics, infectious disease, point-of-care, pharmacy-based diagnostics, commercialization, and reimbursement.
AI
